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ABSTRACT 
3,4-Methylenedioxymethamphetamine (MDMA) is a popular 
recreational drug that has been shown to increase 
serotonin and ·dopamine levels, yet little is know about 
its long-term effects in brain. Recehtly, however, studies 
examining the effects of prenatal MDMA exposure on brain 
functioning have indicated that MDMA exposure may be 
responsible for long-term cognitive deficits. Therefore, 
in the present study we administrated MDMA (20 mg/kg twice 
per day) to both male and female preweanling rats on 
postnatal days (PD) 11-20, to assess whether MDMA caused 
permanent deficits in serotonergic and dopaminergic 
functioning. We measured serotonin, 5-hydroxyindoleacetic 
acid, dopamine, dihydroxyphenyleacetic acid levels, and 
PKA activity in the striatum, prefrontal cortex, and 
hippocampus on PD 90. MDMA pre-exposure caused significant 
reductions in serotonin concentrations in both the 
prefrontal cortex and hippocampus. In addition, the 
striatum and prefrontal cortex showed significant 
reductions in dopamine, however only in the prefrontal 
cortex were significant declines in dihydroxyphenyleacetic 
acid levels observed. MDMA pre-exposed rats showed a 
significant decline in protein kinase A activity in both 
prefrontal cortex and hippocampus. When considered 
iii 
together, this study provides the first evidence that 
exposure to MDMA during the preweanling period has 
long-term neurotoxic effects on both serotonergic and 
dopaminergic systems. 
iv 
ACKNOWLEDGMENTS 
I would like to take the opportunity to acknowledge 
the direct and indirect help of many people who made this 
thesis possible. I wish.to express my appreciation and 
gratitude to my mentor Dr. Sanders McDougall whose 
constant encouragement, support, and patience were always 
present. His expertise and guidance reinforced my 
knowledge and made me a better researcher. Dr. Cynthia 
Crawford too has played an instrumental role in the 
development of my laboratory skills and added to my 
knowledge of neuroscience. Appreciation is also expressed 
to Dr. Robert Cramer for his insightful suggestions. 
Without their help and guidance this project would not 
have ~een possible. It was a pleasure and a privilege to 
collaborate with such special people who contributed so 
much to the successful completion of this thesis. 
My sincere and deepest appreciation goes to my family 
(Dad, Mom, and Scott) for their love, enduring 
encouragement, and understanding throughout the pursuit of 
my master's degree. I love you very much and could not 
have achieved this goal without your support. Thank you 
Fiona for the unconditional friendship, support, and 
numerous lab hours. You have made a difficult journey both 
manageable and exciting. 
V 
I also wish to acknowlege the generous financial 
assistance provided by the Associated Student Incorporated 
(ASI) of California State University, San Bernardino. 
vi 
TABLE OF CONTENTS 
ABSTRACT iii 
CHAPTER ONE: INTRODUCTION 
3,4-Metheylenedioxymethamphetamine (MDMA) 
MDMA-Induced Neurotoxicity: Serotonin 
ACKNOWLEDGMENTS V 
LIST OF FIGURES .. ·.................................... . X 
Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 
Summary and Proposal . . . . . . . . . . . . . . . . . . . . . . . . 3 
Serotonin Systems . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 
Neuropharmacology ........................... 4 
Neuroanatomy and Behavior ................... 7 
Dopamine Systems ................................. 8 
Neuropharmacology ........................... 8 
Neuroanatomy and Behavior ................... 10 
Behavioral Impact of MDMA Exposure ............... 11 
Acute Behavioral Effects of MDMA ............ 11 
Long-Term Behavioral Effects of MDMA 13 
Systems . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 
Acute MDMA Exposure . . . . . . . . . . . . . . . . . . . . . . . . . 17 
Chronic MDMA Exposure ....................... 19 
MDMA-Induced Neurotoxicity: Dopamine Systems ..... 21 
Acute MDMA Exposure . . . . . . . . . . . . . . . . . . . . . . . . . 22 
Chronic MDMA Exposure ....................... 23 
Factors Affecting Neurotoxicity .................. 24 
vii 
Protection from Serotonergic and 
Dopaminergic :r:-Jeurotoxici ty . . . . . . . . . . . . . . . . . . 24 
Effects of Ambient Temperature .............. 25 
MDMA-Induced Effects on Behavior and Neural 
Development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 
Prenatal Drug Exposure . . . . . . . . . . . . . . . . . . . . . . 26 
Postnatal Drug Exposure ..................... 28 
Hypotheses . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . 2 9 
CHAPTER TWO: METHODS AND MATERIALS 
Animals and Rearing Conditions 31 
In Vivo MDMA Administration . . . . . . . . . . . . . . . . . 32 
Protein Kinase A (PKA) Assay ................ 33 
Serotonin (5-HT) and 
5-Hydroxyindoleacetic Acid (5-HIAA) 
Dopamine (DA) and Dihydroxyphenyleacetic 
CHAPTER THREE: RESULTS 
CHAPTER FOUR: DISCUSSION 
Content Assays . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34 
Acid (DOPAC) Content Assays ................. 35 
Data Analysis 35 
Effects of MDMA on Serotonergic Functioning ...... 37 
Effects of MDMA on Dopaminergic Functioning ...... 37 
Effects of MDMA on PKA Activity .................. 38 
Rationale . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 7 
Evidence for MDMA-Induced Neurotoxicity 48 
Serotonergic and Dopaminergic 
Functioning............. . . . . . . . . . . . . . . . . . . . . . 48 
PKA Activity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50 
viii 
Summation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52 
Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54 
REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56 
ix 
LIST OF FIGURES 
Figure 1. Mean (±S.E.M.) 5-HT and 5-HIAA Levels of 
MDMA- and Saline-Pre-Exposed Male and 
Female Rats in Prefrontal Cortex ............ 39 
Figure 2. Mean (±S.E.M.) 5-HT and 5-HIAA levels of 
MDMA- and Saline-Pre-Exposed Male and 
Female Rats in Hippocampus .................. 40 
Figure 3. Mean (±S.E.M.) DA and DOPAC Levels of 
MDMA- and Saline-Pre-Exposed Male and 
Female Rats in Dorsal Striatum .............. 41 
Figure 4. Mean (±S.E.M.) DA and DOPAC Levels of 
MDMA- and Saline-Pre-Exposed Male and 
Female Rats in Prefronatal Cortex ........... 42 
Figure 5. Mean (±S.E.M.) DA and DOPAC Levels of 
MDMA- and Saline-Pre-Exposed Male and 
Female Rats in Striatum ..................... 43 
Figure 6. Mean (±S.E.M.) PKA Activity Levels of 
MDMA- and Saline-Pre-Exposed Male and 
Female Rats in Prefrontal Cortex ............ 44 
Figure 7. Mean (±S.E.M.) PKA Activity Levels of 
MDMA- and Saline-Pre-Exposed Male and 
Female Rats in Hippocampus .................. 45 
Figure 8. Mean (±S.E.M.) PKA Activity Levels of 
MDMA- and Saline-Pre-Exposed Male and 
Female Rats in Dorsal Striatum .............. 46 
X 
CHAPTER ONE 
INTRODUCTION 
3,4-Metheylenedioxymethamphetamine 
(MDMA) Overview 
3,4-Methylenedioxymethamphetamine (MDMA), popularly 
known as "Ecstasy", continues to gain popularity as a 
recreational drug (Cregg & Tracey, 1993; Cuomo, Dyment, & 
Gammino, 1994; Ricaurte, Finnegan, Irwin, & Langston, 
1990), despite compelling evidence that MDMA is a potent 
toxic compound affecting both brain serotonergic (Green, 
Cross, & Goodwin, 1995; Ricaurte, Byran, Stauss, Seiden, & 
Schuster, 1985) and dopaminergic functioning (Hotchkiss & 
Gibb, 1980; Ricaurte, Schuster, & Seiden, 1980; Seiden, 
Fischman, & Schuster, 1975). Illicit use of MDMA did not 
become popular until the lite 1980's among college 
campuses and underground ·"rave" partieso The incidence of 
MDMA usage has escalated rapidly, largeiy due to its 
euphoria-inducing and mild stimulant properties. Although 
first synthesized as a pharmacotherapeutic agent in the 
early: 1900's (Shulgin, 1986), it was quickly abandoned 
! 
until the 1970's, when some mental health professionals 
began using it in,an attempt to facilitate psychotherapy 
(Greer, 1985; Greer & Tolbert, 1986; Shulgin & Nichols, 
1978). Even though both the therapeutic communities and 
1 
recreational drug users displayed intense interest in 
MDMA, the Drug Enforcement Administration (DEA) 
categorized MDMA as a Schedule I synthetic substance 
(Lawn, 1986). Schedule I drugs have a high potential for 
abuse and are not accepted for medical use in the United 
States. 
Due to the drastic increase in the abuse of MDMA, 
researchers have begun to intensively investigate the 
neurobiological effects of MDMA on various neuronal 
parameters. Researchers using animals have shown that MDMA 
affects motor, autonomic, and general central nervous 
system (CNS) functioning (Shulgin, 1986). These effects 
are similar to those observed in humans and include 
hyperactivity, excitability, aggressive behavior, 
convulsions, muscular rigidity, mydriasis, and salivation 
(Hardman, Haavik, & Seevers, 1973). 
Evidence that MDMA causes brain damage is based on 
experiments involving non-primates and primates. For 
example, both acute and chronic treatment with MDMA 
produces significant damage to serotonin (5-HT) neurons in 
rat brain (Battaglia, Yeh, & De Souza, 1988; Ricaurte, 
DeLanney, Irwin, & Langston, 1988). MDMA also alters 
serotonergic functioning in primate brain, as this drug 
causes regional decreases in 5-HT metabolites (e.g., 
2 
5-hydroxyindoleacetic acid; 5-HIAA) and a reduction in 
5-HT uptake sites (Insel, Battaglia, Johannessen, Marra, & 
De Souza, 1989; Ricaurte et al., 1988). MDMA also disrupts 
dopaminergic functioning by altering the activity of 
dopamine (DA) transporters, and by reducing both tyrosine 
hydroxylase (TH) activity and DA levels (Hotchkiss & Gibb, 
1980; Metzer, Hanson, Gibb, & Fleckenstein, 1998; Nash & 
Nichols, 1991; Wagner, Ricaurte,- Seideb, Schuster, Miller, 
& Westley, 1980). Decreased dopaminergic and serotonergic 
neurotransmission has been implicated in cognitive 
impairment and numerous psychiatric disorders (Kahn & 
Davis, 1994; Maes & Meltzer, 1994); thus, it is important 
to determine the neural mechanisms affected by MDMA 
exposure. 
Summary and Proposal 
It appears that MDMA induces neurotoxicity in 
serotonergic and dopaminergic neurons. The purpose of this 
project is to assess the long-term effects of repeated 
administration of MDMA on both serotonergic and 
dopaminergic neuronal functioning. Specifically, male and 
female rats will be given daily administrations of MDMA 
(50 mg/kg twice per day) on postnatal days (PD) 11-20. 
Rats will be killed at PD 90 and samples from the dorsal 
striatum, prefrontal cortex, and hippocampus will be 
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assayed for 5-HT, 5-HIAA, DA, dihydroxyphenyleacetic acid 
(DOPAC) levels, and protein kinase A (PK.A) activity. 
Measuring these neurotransmitters (i.e., 5-HT and DA) is a 
common method for assessing neurotoxicity. In addition, 
PK.A will be measured because it is an important component 
of second messenger systems associated with both 5-HT and 
DA, and PK.A activity is reduced after repeated treatments 
with amphetamine and methamphetamine (Crawford, Zavala, 
Karper, Collins, Loring-Meier, Watson, & McDougall, 2000a; 
Terwilliger, Beitner-Johnson, Sevarino, Crain, & Nestler, 
1991). Thus, this study will attempt to determine whether 
early exposure to MDMA causes neurotoxicity in 5-HT and DA 
neurons or a decline in PK.A activity. 
Serotonin Systems 
Neuropharmacology 
5-HT is a monoamine neurotransmitter found in both 
the CNS and peripheral nervous system (PNS),. 5-HT plays a 
variety of roles in neurological functioning. More 
specifically, 5-HT has been implicated in the etiology or 
treatment of various disorders, such as anxiety, 
depression, schizophrenia, and obesity (Naughton, 
Mulrooney, & Leonard, 2000). Serotonergic neurons are 
principally located in several clusters· along the midline 
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or the raphe of the brainstem. The dorsal raphe is 
situated in the midbrain central gray matter on the 
midline just below the sylvian aqueduct and the median 
raphe is located ventrally on the midline (Feldman, Meyer, 
& Quenzer, 1997). 
5-HT is synthesized in a two-step process from the 
essential amino acid tryptophan. Tryptophan is the 
rate-limiting step in the biosynthesis of 5-HT; therefore, 
the amount of tryptophan in the brain determines the 
amount of 5-HT produced. After tryptophan enters the 
presynaptic terminal the enzyme tryptophan hydroxylase 
converts tryptophan to 5-hydroxytryptophan (5-HTP). Amino 
acid decarboxylase removes a carboxyl group from 5-HTP to 
yield 5-HT (Cox & Nelson, 2000). Free-floating 5-HT is 
rapidly metabolized by MAO and the resulting substance is 
readily converted by aldehyde dehydrogenase to 5-HIAA. 
Thus, 5-HIAA is the major metabolite of 5-HT. 5-HT is 
removed from the synaptic cleft by either an active 
reuptake process or by MAO. Like the dopaminergic reuptake 
system, Na+/cl- is necessary for the 5-HT transporter to 
function (Graham, Esnaud, Habert, & Langer, 1989; 
Marcusson & Ross, 1990). 
Molecular biology techniques have paved the way for 
tremendous progress in 5-HT receptor identification. 5-HT 
5 
can act presynaptically or postsynaptically, and can be 
either excitatory or inhibitory. Thus, it.is no surprise 
that more than 16 different 5-HT receptors have been 
identified (Cryan & Leonard, 2000; Dubovsky & Thomas, 
1995; Teitler & Herrick-Davis, 1994). Currently, 5-HT 
receptors are classified according to their structure into 
three major families of receptors: 5-HT1, 5-HT2 , and 5-HT3 • 
These families of 5-HT receptors can be further subdivided 
into a variety of receptor subtypes [e.g., 5-HT1A, 5-HTrn, 
etc.] (Bradley, Engel, Feniuk, Fozard, Humphrey, 
Middlemiss, Mylechrane, Richardson, & Saxena, 1986; Zifa & 
Fillion, 1992). With the exception of the 5-HT3 receptor, 
which is a ligand-gated ion channel, all other 5-HT 
receptor subtypes are G-protein coupled receptors (Teitler 
& Herrick-Davis, 19~4)·. 5-HT1 receptors have a high 
affinity for 5-HT and stimulation of these receptors 
inhibits adenylase cyclase activity and opens a K+ channel 
producing hyperpolarizations (Chen & Penington, 1996, 
1997; Penington & Fox, 1995; Penington, Kelly, & Fox, 
1993; Premkumar & Ahern, 1995). 5-HT2 receptors are 
low-affinity receptors and activation of these receptors 
can either increase ca++ levels by stimulating 
phosphoinositol hydrolysis or depolarize neurons by 
closing K+ channels (Chen & Penington, 1997, 1996; 
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Penington & Fox, 1995; Penington et al., 1993; Premkumar & 
Ahern, 1995). 
Neuroanatomy and Behavior 
Serotonergic neurons originate in the brain stem and 
project throughout the brain. More specifically, 5-HT 
neurons can be divided into two distinct systems: the 
caudal system and the rostral system (Sanders-Bush & 
Canton, 1995; Tork, 1990). The caudal system, which is 
consistent with Bl-B4 of Dahlstrom and Fuxe (1964), 
originates in the median and paramedian medulla and caudal 
pons, with axons terminating in the spinal cord (Tork, 
1990). These descending pathways are involved in sensory, 
motor, and autonomic functioning (Whitaker-Azmitia, 1991) 
The rostral system, which is consistent with the B5-B9 
cell groups (Dahlstrom & Fuxe, 1964), originates in raphe 
nuclei of the rostral pons, mesencephalon, caudal linear 
nucleus, nucleus pontis oralis, and the supralemniscal 
region (Nieuwenhuys, 1985; Tork, 1990). Fibers projecting 
from these neurons ascend to the diencephalon, basal 
ganglia, limbic system, and cortex via two distinct fiber 
tracts: the ventral and dorsal ascending pathways 
(Nieuwenhuys, 1985). 
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Dopamine Systems 
Neuropharmacology 
DA was initially considered to be merely an 
intermediate step in the synthesis of -norepinephrine and 
epinephrine. In the late 1950's, however, DA was 
discovered to be a neurotransmitter involved in the 
control of motor movement and emotional behaviors (Seeman, 
1995). DA is a catecholamine neurotransmitter synthesized 
in nerve terminals in the hypothalamus, arcuate nucleus, 
caudate, nucleus acccumbens, prefrontal cortex, 
hippocampus, and various other areas of the CNS (Feldman 
et al., 1997; Wolf & Roth, 1987). DA is impermeable to the 
blood brain barrier, thus it must be synthesized in the 
CNS (Cooper, Bloom, & Roth, 1996). Specifically, tyrosine 
readily passes the blood-brain barrier where it is 
actively absorbed into the brain. Upon entry into DA 
terminals, tyrosine is converted to 
L-dihydroxyphenylalanine (L-DOPA) by the enzyme TH. The 
rate at which this conversion takes place is limited by 
the amount of TH present, thus TH is the rate-limiting 
step in DA synthesis. L-DOPA is then quickly converted to 
DA by the enzyme DOPA decarboxylase (Roth & Elsworth, 
1995) . 
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After being released into the synaptic cleft, the DA 
transporter, a Na+/cl- dependent mechanism, transports DA 
in either direction depending on the concentration 
gradient (Krueger, 1990). Thus, in the normal case DA is 
transported from the synaptic cleft to the presynaptic 
terminals where it is either repackaged into vesicles or 
metabolized into DOPAC by the enzyme monoamine oxidase 
(MAO). Extracellular DA can be metabolized by the enzyme 
catechol-0-methyltransferase (COMT) and converted into 
homovanillic acid (HVC), one of the primary metabolites of 
DA (Kopin, 1985). 
DA can inhibit or excite other neurons, depending on 
the properties of the receptor stimulated. There are two 
families of DA receptors differentiated on the basis of 
their pharmacology: Di-like and D2 -like receptors 
(Civelli, 1995; Kebabian & Calne, 1979). These two 
families of receptors include five structurally distinct 
subtypes: Di, D2 , D3 , D4 , and D5 receptors (Cooper et al., 
1996). The Di and D5 receptors (i.e., Di-like receptors) 
are closely related, as they stimulate adenylyl cyclase 
activity, increase cyclic AMP (cAMP), and are excitatory. 
In contrast, D2 , D3 , and D4 receptors (i.e., D2 -like 
receptors) inhibit adenylyl cyclase activity, decrease 
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cAMP activity, and are inhibitory (Andersen, Gingrich, 
Bates, Dearry, Falardeau, & Senogles, 1990). 
Neuroanatomy and Behavior 
Dopaminergic neurons are found in small and large 
circuit pathways in the CNS. The nigrostriatal pathway, 
one of the larger pathways, is the primary DA pathway 
projecting from the substantia nigra and terminating in 
the caudate and putamen (Bannon & Roth, 1983). 
Degeneration of dopaminergic neurons in the .nigrostriatal 
pathway is responsible for motor deficits associated with 
Parkinson's disease (Bannon & Roth, 1983; Cooper et al., 
1991). DA neurons also compose the mesolimbic and 
mesocortical pathways, which originate in the ventral 
tegmental area (VTA) and project to parts of the limbic 
system and cortex, respectively. DA neurons in the limbic 
system modulate both locomotor activity and motivation 
(LeMoal & Simon, 1991); whereas, DA neurons projecting to 
the cortex appear to be involved in cognition and 
emotional behavior (Wolf, Deutch, & Roth, 1987). Excess 
dopaminergic transmission within the mesolimbic and 
mesocortical systems has been linked to schizophrenia 
(Kahn & Davis, 1994), as well as some of the motor and 
attention problems associated with Tourette's disorder and 
attention deficit hyperactivity disorder [ADHD] (Comings, 
10 
Comings, Muhleman, Dietz, Shahbahrami, Tast, Knell, 
Koscsis, Baumgarten, Kovacs, Levy, Smith, Borison, Evans, 
Klein, MacMurray, Tosk, Sverd, Gysin, & Flanagan, 1991; 
George, Robertson, Costa, Ell, Trimble, Pilowsky, & 
Verhoeff, 1994). 
Behavioral Impact of MDMA Exposure 
A substantial number of studies using various species 
have examined the behavioral effects induced by MDMA. 
While many studies have assessed behavioral changes 
induced by acute MDMA treatment other studies. have 
examined the cognitive impact of repeated MDMA exposure. 
Acute Behavioral Effects of MDMA 
The acute behavioral effects characteristic of MDMA 
treatment are caused by a rapid decline in TPH and reduced 
5-HT activity, coupled with increased DA release. 
Behavioral effects of acute MDMA treatment have been 
assessed through a variety of paradigms, including the 
elevated plus-maze, open field, skilled paw-reach tasks, 
and threat and attack paradigms. Paradigms designed to 
assess anxiety sµggest that MDMA's effects are complex. 
For example, on the elevated plus-maze, lower doses of 
MDMA (4 mg/kg) produce an anxiogenic effect in mice, 
whereas at higher doses (20 mg/kg) anxiolytic effects are 
11 
apparent (Lin, Burden, Christie, & Johnson, 1999). In 
contrast, rats given medium to high doses of MDMA display 
an anxiogenic response when assessed on·an elevated 
plus-maze (Bhattacharya, Bhattacharya, & Ghosal, 1998) 
When assessed in the open field, rodents treated with MDMA 
exhibit a decrease in anxiety-related behaviors and an 
increase in locomotor activity (Meehan, Moran, & Elliot, 
2002). Significant impairments in spontaneous locomotor 
activity and skilled motor function are also observed 
after MDMA exposure (Marston, Reid, Lawrence, Oliverman, & 
Butcher, 1999). Lastly, MDMA reduces aggressive behaviors 
in rodents when assessed on threat and attack paradigms 
(Miczek & Haney, 1994). The latter findings are 
interesting, because reductions in 5-HT activity typically 
increase aggressive behaviors in rodents. 
In addition to examining the unlearned effects of 
MDMA exposure, a number of laboratories have examined 
whether MDMA causes cognitive impairments (Bolla, Mccann, 
& Ricaurte, 1998; Curran & Travill, 1997; Morgan, 1999). 
Various tests of memory function (e.g., delayed non-match 
to place and self-ordered spatial search tasks) have 
demonstrated that acute MDMA treatment induces cognitive 
deficits (Marston et al., 1999; Taffe, Weed, Davis, 
Huitron-Resendiz, Schroeder, Parsons, Henriksen, & Gold, 
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2001). More specifically, on the delayed non-match to 
place task, rats treated with MDMA display severe memory 
impairments (Marston et al., 1999). In addition, acute 
MDMA treatment causes a dose-dependent decrease in both 
accuracy and response rates on a delayed non-match to 
sample task in pigeons (Lesage, Clark, & Poling, 1993) 
Rhesus monkeys perform poorly on cognitive battery 
measures after acute treatment with MDMA (Taffe et al., 
2001). These alterations in both unlearned behaviors and 
cognitive functioning are credited to neurochemical 
changes caused by acute MDMA treatment. 
Long-Term Behavioral Effects of MDMA 
It has been well documented that administration of 
MDMA, either in a single high dose or multiple doses, 
produces long-term damage to 5-HT nerve terminals, but the 
long-term behavioral impact of MDMA neurotoxicity remains 
unclear (Molliver, Berger, Mamounas, Molliver, O'Hearn, & 
Wilson, 1990; O'Hearn, Battaglia, De Souza, Kuhar, & 
Molliver, 1988; O'Shea, Granados, Esteban, Colado, & 
Green, 1998). The neurotoxic effects of MDMA exposure 
first appear between 1 and 7 days after drug 
administration and are characterized by a decrease in 5-HT 
concentrations, loss in functional 5-HT uptake sites, and 
degeneration of serotonergic terminals (McKenna & 
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Peroutka, 1990; Schmitt, 1987; Schmitt & Kehen, 1990). 
Brain levels of DA and its metabolites are not affected by 
low doses of MDMA, but are depleted after higher doses. 
This pattern of results suggests that MDMA is capable of 
inducing DA neurotoxicity, and that MDMA is more toxic to 
5-HT than DA neurons (Commins, Vosmer, Virus, Woolverton, 
Schuster, & Seiden, 1987; Laverty & Logan, 1990; Miller & 
O'Callaghan, 1995). 
There is some evidence, although it is not 
conclusive, that MDMA exposure has long-term impact on 
behavioral and cognitive performance. On the elevated 
plus-maze and open field tasks, MDMA-treated rodents 
exhibit. reduced anxiety and increased risk-taking behavior 
(Meehan et al., 2002). However, when behavior is assessed 
using a social interaction paradigm, rats given MDMA have 
fewer social interactions than their controls (Fone, 
Beckett, Topham, Swettenham, Ball, & Maddocks, 2002), 
suggesting that MDMA causes increased social anxiety 
(File, 1980). Studies using rodents indicate that MDMA 
exposure causes long-term cognitive deficits. For example, 
rats treated with MDMA display deficits on a delayed 
non-matching to position working memory task for up to 19 
days after drug treatment (Marston et al., 1999). This 
cognitive deficit, which suggests that MDMA impairs 
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short-term memory, is consistent with the finding that 
MDMA causes degeneration of serotonergic neurons in the 
cortex and hippocampus (Marston et al., 1999). In 
contrast, the performance of rats on a .delayed alternation 
task was generally unaffected by neurotoxic doses of MDMA 
(Ricaurte, Markowska, Wenk, Hatzidimitriou, Wlos, & Olton, 
1993). Consistent with the latter study, primates display 
an absence of learning impairments after exposure to MDMA 
(Frederick, Ali, Sl{kker, Gilliam, Allen, & Paule, 1995). 
Therefore, while it has been well documented that 
MDMA-induces neurotoxicity, much remains to be discovered 
about the behavioral consequences that accompany long-term 
depletion of 5-HT and DA. 
It is uncertain whether MDMA exposure causes 
neurotoxicity in humans, but emerging evidence indicates 
that repeated MDMA exposure results in performance 
decrements in neurocognitive functioning (Morgan, 1999; 
Rodgers, 2000). The manifestations of these deficits, in 
terms of altered cerebral functioning and behavioral 
changes, range from neuroendocrine impairments to deficits 
in verbal memory and reasoning, short-term memory, 
semantic recognition, and visual memory (Broening, 
Morford, Imman-Wood, Fukumura, & Vorhees, 2001; Marston et 
al., 1999; Morgan, 1999; Rodgers, 2000). Therefore, 
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despite some conflicting reports, there is ample evidence 
that MDMA exposure has long-term behavioral impact on both 
animals and humans. Understanding the nature of this 
MDMA-induced neurotoxicity may be important for the 
treatment of personality disorders, impulsive/aggressive 
behavior, and learning impairments. 
MDMA-Induced Neurotoxicity: 
Serotonin Systems 
MDMA exposure causes characteristic patterns of 
neurotoxicity, as MDMA exerts marked effects on 
serotonergic systems in brain (Battaglia, Yeh, O'Hearn, 
Molliver, Kuhar, De Souza, 1987; Schmidt, 1987; Sprague, 
Everman, & Nichols, 1998; White, Obradovic, Imel, & 
Wheaton, 1996). For example, neurochemical studies in 
rodents and primates have demonstrated that MDMA exposure 
results in a profound decrease in 5-HT concentrations 
(Battaglia et al., 1987; Commins et al., 1987; Stone, 
Stahl, Hanson, & Gibb, 1986). In addition, MDMA exposure 
reduces 5-HT transporters and synaptosomal uptake activity 
(Stone et al., 1986), d~creases the density of 5-HT axon 
terminals (Battaglia et al., 1987; Huether, Zhou, & 
Ruther, 1997; O'Hearn et al., 1988), and causes declines 
in 5-HIAA and TPH levels (Battaglia et al., 1987; Schmidt, 
1987; Stone et al., 1986). As mentioned previously, TPH is 
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the rate-limiting step in 5-HT synthesis, and reductions 
in brain TPH activity may be one of the initial neurotoxic 
effects produced by MDMA (Schmidt & Kehne, 1990). 
The neurotoxic effects of' MDMA exposure are often 
quantified by assessing reductions in transporter site 
density using [3 H]-paroxetine (Battaglia et al., 1987). In 
addition, neurotoxic damage to 5-HT nerve terminals can be 
determined by measuring decreases in 5-HT and 5-HIAA 
levels (Battaglia et al., 1987; Hewitt & Green, 1994; 
Stone et al., 1986). Advanced brain imaging techniques, 
such as positron emission tomography (PET), can also be 
used to assess neuronal damage. For example, PET imaging 
indicates that MDMA exposure causes significant reductions 
in the number of 5-HT transporters in various brain 
regions (Commins et al., 1987; Mccann, Szabo, Scheffel, 
Dannals, & Ricaurte, 1998). Most typically, damage to 5-HT 
neurons has been demonstrated in the hippocampus, 
neocortex, striatum, thalamus, and amygdala (Molliver et 
al., 1990; O'Hearn et al., 1988). 
Acute MDMA Exposure 
Acute treatment with MDMA can induce neurotoxicity, 
but the extent of the damage varies according to dose. 
Evidence of neuronal damage has been revealed by the 
application of silver staining techniques, which have 
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shown that a single exposure to MDMA (40 mg/kg) produces a 
substantial increase (90%) in the number of degenerating 
axons and nerve terminals (Commins et al., 19_87; Slikker 
et al., 1988). Similarly, a single injection of 20 or 40 
mg/kg MDMA is capable of inducing 5-HT toxicity in the 
striatum, hippocampus, and cortex; however, neurotoxicity 
in the hypothalamus was only induced by _an injection of 40 
mg/kg MDMA (Commins et al., 1986). Acute treatment with a 
lower dose (10 mg/kg) of MDMA caused a significant decline 
in the density of 5-HT uptake sites in prefrontal cortex 
of rat brain (Battaglia et al., 1988). Likewise, a single 
injection of 10, 15, or 20 mg/kg MDMA caused a significant 
decline in TPH activity and an increase in 
transporter-mediated 5-HT in the neostriatum, hippocampus, 
and hypothalamus of adult rats (Battaglia et al., 1988; 
Ricaurte et al., 1988; Schmidt & Kehne, 1990; Stone, 
Merchant, Hanson, & Gibb, 1987), while an acute injection 
of 15 mg/kg MDMA reduced 5-HT and 5-HIAA levels by more 
than 50% in the cortex, hippocampus, nucleus accumbens and 
striatum (Mayerhofer, Kovar, & Schmidt, 2001; O'Shea et 
al., 1998). 5-HT neurons in the cerebral cortex of monkey 
brain also show structural changes and axonal damage after 
exposure to 5 mg/kg MDMA (Ricaurte et al., 1988). 
Therefore, it is clear that an acute injection of a 
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moderate to high dose (i.e., 10-40 mg/kg) of MDMA causes 
substantial 5-HT neurotoxicity; whether lower doses of 
MDMA induce neurotoxicity is more uncertain. 
Chronic MDMA Exposure 
Repeated administration of MDMA causes 5-HT 
neurotoxicity in animals. MDMA-induced neurodegeneration 
appears to be dosage- and frequency-dependent. Rats 
treated with multiple low doses of MDMA (4 mg/kg), either 
once daily over a four day period or twice weekly over an 
eight week period, show no evidence of 5-HT neurotoxicity 
(O'Shea et al., 1998). When the same study was replicated 
with slight alterations in the frequency of MDMA exposure 
(4 mg/kg twice daily for a four day period) significant 
reductions in 5-HT uptake sites were reported (O'Shea et 
al., 1998). In rhesus monkeys, multiple injections with a 
low dose of MDMA (2.5 mg/kg twice daily for four days) 
reduced 5-HT levels in the hippocampus (Ali, Newport, 
Scallet, Binienba, Ferguson, Bailey, Paule, &.Slikker, 
1993). This is of particular interest because squirrel 
monkeys exposed to 2.5 mg/kg MDMA twice a month for four 
months showed no long-term changes in 5-HT or 5-HIAA 
levels or 5-HT transporter sites (Ricaurte et al., 1988) 
More frequent treatment with MDMA (5 mg/kg twice daily for 
four days) produces substantially more neurotoxicity in 
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monkey brain, as immunostaining indicated that 
serotonergic axons were swollen and fragmented (Ricaurte 
et al., 1988). Based on these studies, it appears that the 
effects of MDMA are both dosage and frequency dependent, 
with larger doses and more frequent drug administrations 
producing greater neurotoxicity (Ali et al., 1993; 
Battaglia et al., 1988; O'Shea et al., 1998; Ricaurte et 
al., 1988). 
Similarly, studies have reported a decrease in 
serotonergic functioning with multipie ·injections of 
higher doses of MDMA. Repeated treatment with 10-40 mg/kg 
MDMA reduces THP activity, 5-HT levels,. and 5-HIAA levels 
by at least 50-60% in the neostriatum, hippocampus, and 
cortex of rat brain (Battaglia et al., 1987; Commins, 
1986; Gibb et al.~ 1990). Likewise, rats given eight 
consecutive injections of 20 mg/kg MDMA over a four day 
period demonstrated up to a 76% depletion of 5-HT 
transporters in the prefrontal cortex, hippocampus, 
striatum, hypothalamus, and midbrain (Battaglia et al., 
1987; Obradovic, Imel, & White, 1996; Schmidt, 1994). 
Thus,. there is an abundance of data showing that repeated 
treatment with moderate to high doses of MDMA causes 
marked 5-HT neurotoxicity and depressed 5-HT functioning 
(Gibb et al., 1990). 
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MDMA-Induced Neurotoxicity: 
Dopamine Systems 
Several in vivo and in vitro studies have shown that 
MDMA robustly evokes the release of DA and induces DA 
neurotoxicity (Nash & Nichols, 1991; Nash & Yamamoto, 
1992; Shankaran & Gudelsky, 1998; Yamamoto & Spanos, 
1988). Furthermore, it has been suggested that there is an 
intimate relationship between DA release and the long-term 
depletion of 5-HT (Nash & Nichols, 1991). That is, MDMA 
releases DA through two separate mechanisms: first, by 
directly releasing DA via the transporter (Johnson, 
Hoffman, Nichols, 1986; Schmidt, Levin, & Lovenburg, 1987) 
and, second, by indirectly releasing DA through actions on 
5-HT systems [the release of 5-HT activates 5-HT receptors 
which stimulates DA synthesis and release] (~cCann & 
Ricaurte, 1993; Nash, 1990). Evidence for the first 
mechanism of action is provided by studies showing that 
selective DA inhibitors (i.e., GBR 12909 and 
a-methyl-p-tyrosine) suppress MDMA-induced DA and 5-HT 
release (Brodkin, Malyala, & Nash, 1993; Stone, Johnson, 
Hanson, & Gibb, 1988). Alt0ough MDMA causes only modest 
depletions of DA, relative to 5-HT, MDMA does induce 
significant DA neurotoxicity in the hippocampus, nucleus 
accumbens, striatum, and other regions of the brain 
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(Johnson et al., 1986; Yamamot.o, Nash, & Gudelsky, 1995; 
Yamamoto & Spanos, 1988) 
Acute MDMA Exposure 
Researchers have found that MDMA-induced 
neurotoxicity not only requires· 5-HT release, but also DA 
efflux from cells (Rudnick & Wall, 1993). Acute treatment 
with low to moderate doses of MDMA (1-20 mg/kg) causes a 
dose-dependent elevation of extracellular DA levels in the 
nucleus accumbens and hippocampus (Kankaanpaa, Meririnne, 
Lillsunde, & Seppala, 1998; Shankaran & Gudelsky, 1998). 
This is of particular interest, because extracellular DA 
promotes free radical formation and inhibits• 
glutamate-evoked firing: two mechanisms responsible for 
neurotoxicity (Cadet, Ladenheim, Hirata, Rothman, Ali, 
Carson, Epstein, & Morgan; 1995; Colado, O'Shea, Grandos, 
Misra, Murray, & Green, 1997i Obradovic et al., 1996; 
Shankaran, Yamamoto, & Gudelsky, 1999; White, Duffy, & 
Kalivas, 1994; Yamamoto & Spanos, 1988). In addition, rats 
exposed to MDMA (1.0, 3.0, or 9.0 mg/kg) show 
significantly depressed DOPAC concentrations, however HVA 
concentrations were only reduced after an acute injection 
of 9:0 mg/kg MDMA (Kankaanpaa et al., 1998). Curiously, an 
earlier study reported that moderate to high doses (10, 
20, or 40 mg/kg) of MDMA does not cause DA neurotoxicity 
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in any of the brain regions examined (Commins et al., 
1986). These results are consistent with other reports 
indicating that MDMA, given at doses which induce 5-HT 
neurotoxicity, leaves the DA system virtually unaltered 
(Battaglia et al., 1987; Colado, O'Shea, Granados, 
Esteban, Martin, & Green, 1999; Schmidt & Kehne, 1990) 
Due to these conflicting results, it remains uncertain 
whether acute MDMA exposure produces measurable DA 
neurotoxicity. 
Chronic MDMA Exposure 
In contrast to the acute administration literature, 
there is more consistent evidence that repeated treatment 
with high doses of MDMA causes DA neurotoxicity (Green et 
al., 1995; Logan, Laverty, Sanderson, & Yee, 1988). 
Although dopaminergic toxicity has been evidenced in both 
primates and non-primates, many of the DA toxicity studies 
use a mouse model (Johnson, O'Callaghan, & Miller, 2002; 
Johnson, Shvedova, Kisin, O'Callaghan, Kommineni, & 
Miller, 2002; O'Shea, Esteban, Camarero, Green, & Colado, 
2001). More specifically, mice treated with MDMA show long 
lasting depletions of striatal DA, HVA, DOPAC, and TH 
(O'Callaghan & Miller, 1994). 
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Factors Affecting Neurotoxicity 
Protection from Serotonergic and Dopaminergic 
Neurotoxicity 
In vivo and in vitro studies have utilized selective 
inhibitors of monoamine transporters to analyze the 
effects of MDMA on serotonergic and dopaminergic neuronal 
systems. Brain dialysis studies have shown that 
pretreating rats with dopaminergic receptor antagonists 
(e.g., haloperidol), DA depletive agents 
(~-methyl-p-tyrosine), selective DA transport inhibitors 
(e.g., GBR 12909), or selective 5-HT transport inhibitors 
(e.g., fluoxetine) will prevent MDMA-induced neurotoxicity 
to DA and 5-HT neurons (Bradberry, 1994; Brodkin et al., 
1993; Colado et al., 1999; Green et al., 1995; Schmidt et 
al., 1991; Stone et al., 1988). For example, rats 
pretreated with haloperidol show an attenuated loss of 
5-HT transporter sites, suggesting that DA release 
contributes to 5-HT transporter destruction (Hewitt & 
Green, 1994). Furthermore, GBR-12909 not only inhibits 
MDMA-induced DA release but attenuates 5-HT neurotoxicity 
(Koch & Galloway, 1997). MDMA-induced 5-HT neurotoxicity 
can also be reduced by serotonergic antagonists 
[fluoxetine, WAY 100135, and methiothepin] (Obradovic et 
al., 1996). For example, pretreatment with selective 5-HT 
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reuptake inhibitors [SSRI's] (e.g., fluoxetine or 
citalopram) block both MDMA-induced 5-RT release and 
subsequent toxicity (Bradberry, 1994; Gudelsky & Nash, 
1996; Schmidt, 1987). Thus, when the release of DA and 
5-RT are blocked by antagonist drugs, the ability of MDMA 
to induce neurotoxicity is. significantly attenuated. 
Effects of Ambient Temperature 
Researchers have also investigated the influence of 
ambient temperature on MDMA-induced neurotoxicity, as it 
has been repeatedly shown that ambient temperature is a 
critical factor in determining the extent of MDMA-induced 
neurotoxicity (Broening, Bowyer, & Slikker, 1995; Malberg 
& Seiden, 1998; Russel & Laverty, 2001). For example, 
MDMA-treated rats maintained at a lower ambient 
temperature (20° or 22° C) display no 5-RT neurotoxicity, 
whereas MDMA-treated rats maintained at a higher ambient 
temperature (26°, 28°, or 30° C) show significant 
decreases in 5-RT and 5-RIAA levels (Malberg & Seiden, 
1998). Ambient temperature probably plays a vital role in 
determining the extent of toxicity because hyperthermia is 
a mechanism responsible for neuronal death (Bowyer, Gough, 
Slikker, Lipe, Newport, & Rolson, 1993; Bowyer, Tank, 
Newport, Slikker, Ali, & Rolson, 1992). Thus, hyperthermia 
is critical for MDMA-induced neurotoxicity, and this 
25 
neurotoxicity can be attenuated by either lowering core 
ambient temperature or by coadministering drugs that 
produce a hypothermic response (Hewitt & Green, 1994; 
Malberg et al., 1996). 
MDMA-Induced Effects on Behavior 
and Neural Development 
Prenatal Drug Exposure 
Several teratological studies have attempted to 
identify possible adverse effects caused by prenatal drug 
exposure. This is of importance because clinical studies 
have reported that human infants exposed prenatally to 
psychostimulant drugs exhibit many neurobehavoral 
problems, such as increased irritability, impairments in 
orientation and motor ability reflexitivity, and 
depression of interactive behavior (Chasnoff,· Burnes, 
Schnoll, & Burnes, 1985; Chasnoff, Griffith, MacGregor, 
Derkes, & Burnes, 1989; Chasnoff & Lewis, 1987). Animal 
models have shown long-term alterations in behavior after 
in utero drug exposure. These alterations include 
modifications in locomotor activity and deficits in 
information acquisition (Heyser, Chen, Miller, Spear, & 
Spear, 1990). For instance, one study reported that 
prenatal cocaine exposure results in long-lasting 
alterations in brain metabolism, including decreased 
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glucose utilization along with increased D1 receptor 
concentrations in the substantia nigra of adult male 
offspring (Dow-Edwards, Freed, & Fico, 1990). 
Surprisingly, relatively few studies have examined 
the effects of prenatal MDMA exposure on brain functioning 
(Aguirre, Barrionuevo, Lasheras, & Del Rio, 1998; Colado 
et al., 1997; St. Omer, Ali, Rolson, Duhart, Scalzo, & 
Slikke_r, 1991). Although MDMA induces neurotoxicity in 
adult rats, results indicate that administering MDMA 
during gestation has no effect on postnatal neurochemical 
development of the 5-HT system (St. Omer et al., 1991) 
More specifically, pregnant rats administered varying 
doses of MDMA (2.5 and 10.0 mg/kg on alternate gestational 
days 6-18) had offspring with normal numbers of 5-HT 
transporters, and 5-HT and 5-HIAA levels remained 
unaffected (St. Omer et al., 1991). This is of interest 
because MDMA caused significant reductions in the 5-HT and 
5-HIAA levels of the dams (St. Omer et al., 1991). 
When all of these results are considered together, it 
is surprising that MDMA exposure does not affect neonates. 
One possibility is that MDMA lacks impact because neonates 
have underdeveloped transporter mechanisms (St. Omer et 
al., 1991). Alternatively, extracellular DA levels may not 
be great enough to produce oxidative stress in 5-HT 
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terminals (Aguirre et al., 1998) or neonates may have a 
higher capacity to scavenge free radicals (Colado et al., 
1997; Sprague et al., 1998). In any event, it appears that 
in utero MDMA exposure does ··not induce measurable 
neurotoxcicty in rats. 
Postnatal Drug Exposure 
Studies examining the neurochemical consequences of 
MDMA exposure during the early pos~natal period are 
sparse. However, most studies suggest that preweanling 
rats, like neonates, are resistant to MDMA-induced 
neurodegeneration (Aguirre et al., 1998; Broening et al., 
1994). In contrast, a recent report indicates that early 
postnatal MDMA exposure does indeed have long-term 
cognitive effects (Broening et al., 2001). The study 
focused on two dosing periods (postnatal day [PD] 1-10 and 
PD 11-20) and four doses of MDMA (0, 5.0, 10.0, and 20.0 
mg/kg, given twice daily). Results indicated that MDMA 
exposure on PD 11-20 significantly disrupted both 
sequential and spatial learning of rats tested on a 
Multiple-T water maze (Broening et al., 2001). More 
specifically, PD 11-20 rats exhibited consistent deficits 
in se'quential learning, measured in terms of errors and 
escape latencies on the Multiple-T water maze, whereas 
rats given MDMA on PD 1-10 did not show any behavioral 
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deficits (Broening et al., 2001; Vorhees, Ahrens, 
Acuff-Smith, Schilling, & Fisher, 1994). Therefore, it.is 
apparent that repeated treatment with MDMA during the 
preweanling period has long-term behavioral impact. The 
neural mechanisms responsible for these behavioral effects 
are uncertain, but probably reflect long-term changes in 
the functioning of 5-HT or DA systems, because MDMA acts 
as an agonist at 5-HT and DA synapses. 
Hypotheses 
In adult animals, repeated exposure to MDMA causes 
5-HT neurotoxicity. In particular, MDMA induces a massive 
release of 5-HT, resulting in depleted levels of 5-HT, 
reduced concentrations of 5-HIAA, decreased activity of 
TPH, and neurodegeneration of 5-HT axon terminals. In 
addition to altering 5-HT systems, MDMA, to a lesser 
extent, impacts DA systems. The purpose of this thesis, 
therefore, was to determine whether exposing rats to MDMA 
during the preweanling period causes long-term measurable 
changes on various indices of 5-HT and_DA functioning. The 
preweanling rat was chosen as the animal model because 
Broening et al. (2001_) have -recently shown that early 
postnatal MDMA exposure causes long-term learning and 
memory deficits. It was hypothesized that rats exposed to 
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repeated high doses of MDMA would show a decreased levels 
of 5-HT, 5-HIAA, DA, DOPAC and reduced PKA activity in 
dorsal striatum, prefrontal cortex, and hippocampus. These 
neuronal changes would be consistent with the hypothesis 
that repeated MDMA exposure during the preweanling period 
causes long-term damage to 5-HT and DA neurons in rat 
brain. 
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CHAPTER TWO 
METHODS AND MATERIALS 
Animals and Rearing Conditions 
Nulliparous female (151-175 g) Sprague-Dawley CD rats 
were obtained from Charles River Laboratories (Raleigh, 
NC). Rats were allowed to acclimate to housing conditions 
in the vivarium at the Cincinnati Children's Hospital 
Research Foundation for at least two weeks prior to 
breeding. Rats were pair housed in polycarbonate cages 
with lights on from 6:00 to 20:00. Food and water were 
freely available. On the day of breeding, one female was 
placed with one male Sprague-Dawley CD rat in a hanging 
wire cage until a sperm plug was detected [embryonic day O 
(ED O)], or until the female had_been with the. male for 2 
weeks. Two weeks after being placed with the male, the 
females were transferred back to polycarbonate cages and 
singly housed. The presence of a litter was checked twice 
daily starting on ED 21 and the day of birth was 
considered postnatal day O (PD 0). Litters remained 
undisturbed until PD 1, at which time litters were culled 
to ten pups (six males and four females). Subjects were 
treated according to the National Institute of Health 
guidelines for the care and use of laboratory animals 
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(Principles of Laboratory Animal Care, NIH Publication 
#85-23) under research protocols approved by the 
Institutional Animal Care and Use Committees of the 
Cincinnati Children's Hospital Research Foundation and 
California State University, San Bernardino. 
In Vivo MDMA Administration 
Each animal in the litter was randomly assigned to 
receive either MDMA or saline (n = 7 males and females per 
group). MDMA HCl (20 mg/kg, expressed as the freebase) or 
saline vehicle were administered twice daily from PD 11-
20. MDMA and saline were injected subcutaneously in the 
back at a volume of 3 ml/kg. Injection sites were rotated 
to ensure the surrounding dermis did not become 
aggravated. Animals were weighed prior to each injection 
and thereafter at weekly intervals. On approximately PD 60 
the animals were shipped to the vivarium at California 
State University, San Bernardino. Rats were left 
undisturbed until PD 90, when they were killed by rapid 
decapitation. Brains were quickly removed and dorsal 
striatal (i.e., caudate~putamen), prefrontal cortex, and 
hippocampus were dissected on dry ice and stored at -80°C 
until time of assay. 
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Protein Kinase A (PKA) Assay 
PKA assays were performed using the Protein Kinase A 
(cAMP-dependent protein kinase) Assay System protocol 
(Life Technologies, Grand Island, NY) with slight 
modifications. Briefly, frozen striatal and prefrontal 
cortex sections were placed in homogenization buffer [50 
mM Tris (pH 7.4), 100 ng/ml leupeptin, 100 ng/ml 
aprotinin, and 5 mM EDTA] and homogenized using a 
hand-held Teflon homogenizer. Protein concentrations were 
determined using the Bio-Rad Protein Assay (Bio-Rad 
Laboratories, Hercules, CA) based on the method of 
Bradford (1976), using bovine serum albumin (BSA) as a 
standard. 
Duplicate striatal homogenates containing 4 µg of 
protein for each subject were incubated for 5 min at 30°C 
in phosphorylation buffer [50 mM Tris (pH 7.4), 10 mM 
MgC1 2 , and 0.25 mg/ml BSA], containing 50 µg of kemptide 
and 100 µM [y- 32 P]ATP (ICN, Costa Mesa, CA). In addition, 
the buffer contained either cAMP (10 µM) or PKI(6-22) 
amide (1 µM/reaction). Following incubation, the 
phosphorylation mixture was blotted on phosphocellulose 
units (SpinZyme Format). Phosphocellulose units were 
centrifuged at 20,000 x g £or 30 s, upon completion 500 ml 
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wash solution and 75 mM phosphoric acid were added and the 
samples were centrifuged again. Buckets were then 
transferred into a new receptacle and 500 ml of wash 
solution was added and centrifuged at 20,000 x g for 30 s. 
Filters were then placed in scintillation fluid and 
quantified by liquid scintillation spectrometry. 
cAMP-dependent PKA activity was defined as the difference 
between PKA activity in the presence of cAMP and that 
measured in the presence of PKI. 
Serotonin (5-HT) and 5-Hydroxyindoleacetic Acid 
(5-HIAA) Content Assays 
Frozen striatal, prefrontal cortex, and hippocampal 
sections were sonicated in 10 volumes of 0.1 N HC1O4 and 
centrifuged at 20,000 x g for 30 min at 4°C. The 
supernatant was then filtered through a 0.22 µm 
centrifugation unit at 2,000 x g for 5 min at 4°C. The 
remaining pellet from each tissue sample was resuspended 
in 0.1 N HC1O4 and used for protein determination. Twenty 
microliters of the resulting extracts were then assayed 
for 5-HT and 5-HIAA using high performance liquid 
chromatography (582 pump and an MD-150 column; ESA, 
Chelmsford, MA) with electrochemical detection (Coulochem 
II; ESA). The mobile phase consisted of 75 mM NaH2PO4 , 1.4 
mM 1-octane sulfonic acid, 1o·mM EDTA, and 10% 
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acetonitrile [MD-TM Mobile Phase (pH 3.1); ESA] and was 
pumped at a rate of 0.5 ml/min. 
Dopamine (DA) and Dihydroxyphenyleacetic Acid 
(DOPAC) Content Assays 
Frozen striatal, prefrontal cortex, and hippocampal 
sections were sonicated in 10 volumes of 0.1 N HC1O4 and 
centrifuged at 20,000 x g for 30 min at 4°C. The 
supernatant was then filtered through a 0.22 µm 
centrifugation unit at 2,000 x g for 5 min at 4°C. The 
remaining pellet from each tissue sample was resuspended 
in 0.1 N HC1O4 and used for protein determination. Twenty 
microliters of the resulting extracts were then assayed 
for DA and DOPAC using high performance liquid 
chromatography (582 pump and an MD-150 column; ESA, 
Chelmsford, MA) with electrochemical detection (Coulochem 
II; ESA). The mobile phase consisted of 75 mM NaH2PO4 , 1.4 
mM 1-octane sulfonic acid, 10 mM EDTA, and 10% 
acetonitrile [MD-TM Mobile Phase (pH 3.1); ESA] and was 
pumped at a rate of 0.5 ml/min. 
Data Analysis 
Analyses of variance (ANOVA) were used to analyze 
PKA, DA, DOPAC, 5-HT, and 5-HIAA data. Litter effects were 
controlled by treating litter as a random factor in all 
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analyses (see Hughes, 1979). In all cases, alpha were set 
at 0.05. 
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CHAPTER THREE 
· RESULTS 
Effects of MDMA on Serotonergic 
Funct,ioning 
Rats pre-exposed to MDMA during the preweanling 
period had significantly lower 5-HT levels in the 
prefrontal cortex than saline controls (see upper graph, 
Figure 1) [drug main effect, F(l,18) = 12.22, p < .01]. 
5-HIAA levels in the prefrontal cortex also appeared to be 
depressed relative to saline controls, but the differences 
between the saline- and MDMA-pre-exposure groups did not 
reach statistical significance (see lower graph, Figure 
1) . 
Overall, when compared to saline controls, MDMA 
significantly lowered 5-HT levels in the hippocampus (see 
upper graph, Figure 2) [drug main effect, F(l,18) = 87.06, 
p < .01]. In addition, male rats had lower levels of 
5-HIAA then females [sex main effect, F(l,18) = 7.53, 
p < .05]. MDMA pre-exposure did not affect 5-HT or 5-HIAA 
levels in the striatum (see Figure 3). 
Effects of MDMA on Dopaminergic 
Functioning 
Examination of the prefrontal cortex revealed 
significantly lower DA levels in rats pre-exposed to MDMA 
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during the preweanling period (see upper graph, Figure 4) 
[drug main effect, F(l,18) = 5.83, p < .05]. Unexpectedly, 
DOPAC levels varied according to sex, since male rats 
displayed significantly lower DOPAC levels in the 
prefrontal cortex then. females (see lower graph, Figure 4) 
[sex main effect, F(l,18) = 4.70, p < .05]. 
DA levels in the dorsal striatum varied according to 
both sex and drug, as only male rats pre-exposed to MDMA 
showed a significant decline in striat~l DA levels (see 
upper graph, Figure 5) [drug x sex interaction, 
F(l,18) = 4.79, p < .05]. DOPAC levels in the dorsal 
striatum did not vary according to group (see lower graph, 
Figure 5). DA and DOPAC levels in the hippocampus were 
nearly undetectable, so results were not reported. 
Effects of MDMA on PKA Activity 
Rats pre-exposed to MDMA during the preweanling 
period showed a significant decline in PKA activity in the 
prefrontal cortex (see Figure 6) [drug main effect, 
F(l,18) = 10.85, p < .05]. Examination of the hippocampus 
also revealed that MDMA exposure caused a significant 
reduction in PKA activity (see Figure 7) [drug main 
effect, F(l,18) = 6.66, p < .05]. MDMA-exposure did not 
significantly affect dorsal striatal PKA activity, 
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although female rats had greater PKA activity in the 
striatum then male rats [see Figure 8] (drug main effect, 
F(l,18) = 5.33, p < .05). 
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CHAPTER FOUR 
DISCUSSION 
Rationale 
Convincing evidence now exists that MDMA exposure 
induces both acute and chronic behavioral and 
neurochemical changes (Bhattacharya et al., 1998; Commins 
et al., 1987; Marston et al., 1999; Morgan, 1999; Nash & 
Nichols, 1991; O'Shea et al., 1998). Although the exact 
method by which MDMA induces neurotoxicity remains to be 
elucidated, systemic administration of MDMA appears to 
cause selective and pronounced alterations in both central 
serotonergic and dopaminergic functioning (Battaglia et 
al., 1988; Hotchkiss & Gibb, 1980; Insel et al., 1989; 
Ricaurte et al., 1988). Even though there is sufficient 
data to indicate that MDMA produces neurochemical 
alterations in adults, little is known about the possible 
adverse effects of MDMA exposure on early brain 
development and functioning. Thus, the purpose of the 
present study was to determine whether exposure to MDMA 
during the preweanling period produced long-term changes 
in various indices of 5-HT and DA functioning. 
To that end, male and female rats were pre-exposed to 
MDMA (20 mg/kg, twice daily) on PD 11-20 and then 
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sacrificed on PD 90. Neurotoxic damage to 5-HT and DA 
terminals was determined by measuring decreases in 5-HT, 
5-HIAA, DA, and DOPAC levels. Because repeated early 
treatment with AMPH and METH causes long-term changes in 
PKA activity (Crawford et al., 2000a, 2000b, 2003), we 
also examined whether pre-exposure to MDMA would cause a 
long-term decline in PKA activity in various brain 
regions. 
Evidence for MDMA-Induced 
Neurotoxicity 
Serotonergic and Dopaminergic Functioning 
Overall, results from the present study indicate that 
MDMA exposure during the preweanling period caused 
neurotoxicity in various brain regions. For example, 
chronic MDMA exposure produced a significant decrease in 
5-HT and DA levels in prefrontal cortex (the metabolites 
did not differ). Early exposure to MDMA also caused 
long-term reductions in hippocampal 5-HT levels, 
suggesting that ~DMA was responsible for hippocampal 
neurotoxicity. The dorsal striatum also evidenced some 
neurotoxicity, as DA levels, but not 5-HT levels, were 
depressed in theJMDMA group. The latter result was 
I 
surprising, because both MDMA and METH cause robust 5-HT 
reductions in adult rat and monkey striatum (De Souza, 
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Battaglia, & Insel, 1990; Kankaanpaa et al., 1998; Nash & 
Nichols, 1991; O'Callaghan & Miller, 1994; Pu & Vorhees, 
1995). 
In the present study, MDMA-induced neurotoxicity was 
indirectly inferred by measuring regional reductions in 
5-HT and DA levels. There is a substantial literature 
showing that prolonged reductions in neurotransmitter 
levels reflects cellular neurotoxicity (for reviews, see 
Commins et al., 1987; Ricaurte et al., 1985; Schmidt et 
al., 1986; Stone et al., 1986). For example, decreases in 
5-HT and DA concentrations are associated with a loss of 
functional 5-HT and DA uptake sites, indicating damage to 
both the serotonergic and dopaminergic nerve terminals 
(Schmidt, 1987; Schmidt et al., 1987). Furthermore, 
Ricaurte et al. (1985) found morphological evidence of 
nerve degeneration in brain regions corresponding to those 
in which drug treatments had produced selective 
long-lasting reductions in serotonergic neuronal markers. 
In addition, histological evidence also revealed 
degenerating neuronal cell bodies through out various 
brain regions having reduced 5-HT and DA levels (Commins 
et al., 1987; Ricaurte· et al., 1985; Schmidt et al., 
1986). Thus, analyzing 5-HT and DA levels, although an 
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indirect method for quantifying neuronal damage, is a 
valid and recognized measure of neurotoxicity. 
PKA Activity 
PKA is a central component of the cAMP second 
messenger system (Taylor et al., 1990). A number of 
studies have suggested that PKA activity is intimately 
involved in the mediation of various behaviors, such as 
locomotor activity, memory, reward-related learning, and 
anxiety (Abel, Nguyen, Barad, Deuel, Kandel, & 
Bourtchouladze, 1997; Berringer & Miller, 1998; Micheau & 
Riedel, 1999; Schafe & LeDoux, 2000; Tolliver, 1999). This 
is of particular interest, because repeated· 
psychostimulant treatment alters PKA activity (Crawford et 
al., 2000a; 2000b, 2003; Nestler & Aghajanian, 1997). More 
specifically, recent studies have described long-term 
reductions in striatal and accumbal PKA activity following 
AMPH (2.5-5.0 mg/kg/day) and METH (40 mg/kg/day) exposure 
during the preweanling period; thus, it is possible that 
drug-induced changes in PKA activity may have substantial 
long-term behavioral impact (Crawford et al., 2000a, 
2003) .. 
To date, no studies have examined the long-term 
effects of developmental exposure to MDMA on PKA activity. 
In the present study, rats given MDMA on PD 11-20 showed 
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reduced levels of PKA activity in the prefrontal cortex 
and hippocampus. Crawford et al. (2000a, 2000b) have 
previously postulated that psychostimulant-induced 
alterations in the DA system (e.g., an up-regulation of 
D2 -like receptors or a down-regulation of D1 -like 
receptors) by altering cAMP system functioning may have 
depressed PKA activity (Crawford et al., 2000a, 2000b). 
The present results are consistent with this explanation. 
However, in the present study we found that MDMA caused a 
robust reduction in prefrontal and hippocampal 5-HT 
levels. Some of the 5-HT receptor subtypes (i.e., 5-HT1a, 
5-HT1b, 5-HT1d, 5-HT1e, 5-HT4, 5-HT6 , & 5-HT7) utilize the 
cAMP second messenger system (Cooper et al., 1996), so it 
is possible that alterations in 5-HT could be one of the 
driving forces (along with DA) responsible for 
MDMA-induced changes in PKA activity. This possibility is 
indirectly supported by results showing that those brain 
areas exhibiting the greatest reductions in 5-HT levels 
also exhibited the greatest reductions in PKA activity. 
Although the exact neural mechanisms have not been 
determined, it is possible that MDMA's ability to reduce 
neuronal 5-HT and DA levels is responsible for the decline 
in PKA activity. 
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Although MDMA's actions were generally similar in 
both sexes, it is curious that only male rats showed an 
MDMA-induced reduction in striatal DA levels. This pattern 
of results has been r._eported before,. since male rats are 
often found to be more susceptible to 
psychostimulant-induced neurotoxicity (for a review, see 
Dluzen, 2000). Past research has shown that c~rculating 
estrogen reduces the neurotoxic effects of AMPH and METH 
(Gao & Dluzen 2001; Wagner, Tekirian, & Cheo, 1993), and 
the present results are consistent with the hypothesis 
that the neuroprotective effects of estrogen may extend to 
MDMA. Additional sex differences were also apparent, as 
male rats had lower levels of hippocampal 5-HIAA and 
prefrontal DOPAC then female rats. The importance of the 
latter findings is uncertain. 
Summation 
As mentione_d earlier, MDMA reduces TPH activity, 5-HT 
transporter sites, and causes degeneration of 5-HT axon 
terminals in adult animals (Battaglia et al., 1987, 1988; 
O'Shea et al., 1998). MDMA has also been shown to affect 
DA functioning in adults. More specifically, MDMA alters 
the number of DA transporters, and reduces both TH 
activity and DA levels in adult animals (Hotchkiss & Gibb, 
52 
1980; Metzer et al., 1998; Nash & Nichols, 1991; Wagner et 
al. , 19 8 0) . 
Few studies ·have examined whether fetal brain damage 
occurs when pregnant dams are exposed to MDMA. However, 
available evidence suggests that MDMA exposure during 
gestation has little effect on postnatal neurochemical 
development (St. Omer et al., 1991). It has also been 
reported that preweanling rats pre-exposed to MDMA on PD 
1-10 do not exhibit neuronal or behavioral deficits 
(Broening et al., 2001; St. Omer et al., 1991). Only 
recently has it become clear that exposing rats to MDMA on 
PD 11-20 causes long-term deficits in cognitive 
functioning (Broening et al., 2001). Importantly, the late 
preweanling period in rats (i.e., PD 11-20) is roughly 
analogous to the late 3rd trimester of human brain 
development (Bayer, Altman, Russo, & Zhang, 1993). Thus, 
the present study has provided new evidence suggesting 
that MDMA e~posure can cause neurotoxic effects at doses 
that approach or mimic those used by recreational MDMA 
users (Ricaurte & Mccann, 1992). Of special concern are 
pregnant MDMA users who expose their unborn fetus is to 
MDMA and, in this way, increase the risk of neurological 
damage at developmental brain stages. 
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More generally, psychological disorders and 
psychiatric symptoms, such as panic attacks 
(Whitaker-Azmitia & Anderson, 1989), depression (Cohen, 
I 
1996), and suicidal ideation (Benazzi & Mazzoli, 1991) 
have been associated with MDMA use. The question continues 
to surface whether there is a causal link between MDMA ~se 
and.the development of psychiatric disorders or whether 
MDMA exacerbates a neurological condition among 
individuals predisposed (Spitzer, Franke, Walter, 
Buechler, .Wunderlich, Schwab, Kovar, Hermle, & Gron, 
2001). If MDMA is neurotoxic in humans, as has been shown 
in other species, then it is likely that the wide-spread 
use of MDMA will present a major public health problem in 
years to come. 
Conclusion 
The present study has demonstrated that repeated 
exposure to MDMA produces long-term damage to serotonergic 
and dopaminergic neurons in various regions of rat brain. 
This conclusion is supported by data showing that MDMA 
pre-exposure: (a) decreased 5-HT levels in prefrontal 
corte.x and hippocampus; (b) decreased DA levels in 
prefrontal cortex and dorsal striatum; and (c) reduced PKA 
activity in p~efrontal cortex and hippocampus. Other 
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investigators have examined the effects of early 
MDMA-exposure on a variety of behavioral and cognitive 
paradigms. For example, data indicate that MDMA exposure 
during the late preweanling period causes significant 
disruptions in sequential and spatial reference 
memory-based learning (Broening et al., 2001). These 
behavioral deficits could potentially be accounted for by 
MDMA-induced reductions in 5-HT and DA levels, as well as 
by changes in PKA activity. Thus, our findings not only 
increase our knowledge of the neurochemical changes 
produced by early MDMA exposure, they also provide insight 
into human brain neurotoxicity_and those MDMA-induced 
changes that may be responsible for learning and memory 
deficits and psychiatric disorders. 
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